Nucleoside analogs with carboxamidine modified monocyclic base

Details Nucleoside analogs with carboxamidine modified monocyclic base Nucleoside analogs with carboxamidine modified monocyclic base

2002-08-22

2009-12-29

Lewis, Patrick T (Department: 1623)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C514S04400A, C514S045000, C536S026900, C536S027200

Reexamination Certificate

active

07638496

ABSTRACT:
Novel nucleoside analog compounds are disclosed. The novel compounds or pharmaceutically acceptable esters or salts thereof may be used in pharmaceutical compositions, and such compositions may be used to treat an infection, an infestation, a neoplasm, or an autoimmune disease. The novel compounds may also be used to modulate aspects of the immune system, including modulation of Type 1 and Type 2 activity.

REFERENCES:
patent: 3798209 (1974-03-01), Witkowski et al.
patent: 3962211 (1976-06-01), Townsend et al.
patent: 3984396 (1976-10-01), Witkowski et al.
patent: 3991078 (1976-11-01), Witkowski et al.
patent: 4093624 (1978-06-01), Revankar et al.
patent: RE29835 (1978-11-01), Witkowski et al.
patent: 4892865 (1990-01-01), Townsend et al.
patent: 4950652 (1990-08-01), Carter
patent: 5290540 (1994-03-01), Prince et al.
patent: 5506347 (1996-04-01), Erion et al.
patent: 5573764 (1996-11-01), Sykes et al.
patent: 5665721 (1997-09-01), Bhagwat et al.
patent: 5674998 (1997-10-01), Boyer et al.
patent: 5767097 (1998-06-01), Tam
patent: 5907036 (1999-05-01), Ramasamy et al.
patent: 6063628 (2000-05-01), Loeb et al.
patent: 6130326 (2000-10-01), Ramasamy et al.
patent: 6277836 (2001-08-01), Borody
patent: 6423695 (2002-07-01), Tam et al.
patent: 6455508 (2002-09-01), Ramasamy et al.
patent: 6495677 (2002-12-01), Ramasamy et al.
patent: 6518253 (2003-02-01), Tam
patent: 6552183 (2003-04-01), Ramasamy et al.
patent: 6573248 (2003-06-01), Ramasamy et al.
patent: 6610665 (2003-08-01), Bays et al.
patent: 2198940 (1996-03-01), None
patent: 0286224 (1988-10-01), None
patent: 0308066 (1989-03-01), None
patent: 0312222 (1989-04-01), None
patent: 0341065 (1989-11-01), None
patent: 0343945 (1989-11-01), None
patent: 0346132 (1989-12-01), None
patent: 64-026593 (1989-01-01), None
patent: 228390 (1991-12-01), None
patent: 330784 (1999-02-01), None
patent: 94028670 (1994-04-01), None
patent: WO 89/05649 (1989-06-01), None
patent: WO 94/07479 (1994-04-01), None
patent: WO 94/22887 (1994-10-01), None
patent: WO 97/26883 (1997-07-01), None
patent: WO 98/16184 (1998-04-01), None
patent: WO 98/16186 (1998-04-01), None
patent: WO 98/39342 (1998-09-01), None
patent: WO 98/39344 (1998-09-01), None
patent: WO 99/45016 (1999-09-01), None
patent: WO 01/27114 (2001-04-01), None
Gabrielsen, B. et al., “Synthesis and Antiviral Evaluation of N-carboxamidine-sbustituded Analogs . . . ,” Journal of Med. Chem., p. 3231-3238, (Aug. 13, 1992).
Witkowski, J. et al., “Synthesis and Antiviral Activity of 1,2,4-Triazole-3-thiocarbxamide . . . ,” Journal of Med. Chemistry, vol. 16 (No. 8), p. 935-937, (Aug. 13, 1973).
“Target Crohn's and Colitis,”Association of the British Pharmaceutical Industry, Feb. 2002.
Definition of “prodrug” Mondofacto On-line Medical Dictionary (copyright 1997-2003- the Cancer Web Project).
FDA Clinical Trials on Inflammatory Bowel Disease (See, Study 2, dated Nov. 3, 1999).
Anderson et al. “Ribonucleosides structurally related to the antitumor antibiotic sangivamycin”J. Org. Chem. 42: 997-1000 (1977).
Andreone et al., In vitro effect of thymosin-alpha1 and interferon-alpha on Th1 and Th2 cytokine synthesis in patients with chronic hepatitis C,J. Viral Hepatitis8:194-201 (2001).
Azar et al., “Type I (Insulin-dependent) diabetes is a Th1- and Th2-mediated autoimmune disease”Clin. Diagnos. Lab. lmmunol.6:306-310 (1999).
Barnard, D., “Viramidine Ribapharm”Curr. Opin. Inv. Drugs3:1585-1589 ((2002).
Begemann et al., “Enhancing the response to interferon-alpha”J. Clin. Virol.13:1-7 (1999).
Berry et al., “Synthesis and Biological Activity of the Novel Adenosine Analogs,”Nucleosides Nucleotides, 13(1-3), 405-420 (1994).
Bonnet et al., “Modulation of leukocyte genetic expression by novel purine nucleoside analogues. A new approach to antitumor and antiviral agents”J. Med. Chem. 36:635-653 (1993).
Bradley et al., “Islet-specific Th1, but not Th2, cells secrete multiple chemokines and promote rapid induction of autoimmune diabetes”J. lmmunol. 162:2511-2520 (1999).
Brillanti et al., “A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C”Gastroenterology107:812-817 (1994).
Chen, “Guanosine derivatives as immunosimmulants, discovery of loxoribine”Nucleosides Nucleotides13(1-3):551-562 (1994).
DeClercq et al., “Antirhinovirus activity of purine nucleoside analogs,”Antimicrobial Agents and Chemotherapy, 29:482-487 (1986).
Edwards et al., “The effect of an intralesional sustained-release formulation of interferon alfa-2b on basal cell carcinomas”Arch. Dermatol. 126(8)1029-1032 (1990).
Eppstein et al., “Liposomal interferon-beta: sustained release treatment of simian varicella virus infection in monkeys”J. Infect. Dis. 159(4):616-620 (1989).
Fan et al., “Circulating Th1 and Th2 cytokines in patients with hepatitis c virus infection”Mediators of Inflammation7:295-297 (1998).
Fraschini et al., “Ribavirin influence on theophylline plasma levels in adult and children”Int. J. Clin. Pharmacol. Ther. Toxicol.26:30-32 (1988).
Gabrielsen et al., “Synthesis and antiviral evaluation of N-carboxamidine-substituted analogues of 1-beta-D-ribofuranosyl-1,2-4-triazole-3-carboxamidine hydrochloride”J. Med. Chem., 35:3231-3238 (1992).
Gallichan et al., “Pancreatic IL-4 expression results in islet-reactive Th2 cells that inhibit diabetogenic lymphocytes in the nonobese diabetic mouse”J. lmmunol.163:1696-1703 (1999).
Gerlach et al., “Recurrence of hepatitis C virus after loss of virus-specific CD4(+) T-cell response in acute hepatitis C”Gastroenterol. 117:933-941 (1999).
Girardet et al. “Synthesis and citotoxicity of 4-amino-5oxopyridol{2,3-d] pyrimidine nucleosides”J. Med. Chem.43:3704-3713 (2000).
Golumbek et al., “Controlled release, biodegradable cytokine depots: a new approach in cancer vaccine design”Cancer Res. 53:5841-5844 (1993).
Hanna et al., “Synthesis of Certain 5′-Substituted Derivatives of Ribavirin and Tiazofurin,” Nucleosides Nucleotides, 5(4), 343-362 (1986).
Hassig et al., “The role of the Th-1 to Th-2 shift of the cytokine profiles of CD4 helper cells in the pathogenesis of autoimmune and hypercatabolic diseases”Med. Hypotheses51:59-63 (1998).
Hinshaw et al., “A study on the relative chemical reactivity of the 5-cyano group of the nucleoside antibiotic toyocamycin and desaminotoyocamycin. The synthesis of analogs of sangivamycin”J. Org. Chem. 35:236-241 (1970).
Hohlfeld, “Biotechnological agents for the immunotherapy of multiple sclerosis”Brain120:865-916 (1997).
Jiang et al., “In vitro and in vivo growth inhibition of SC-M1 gastric cancer cells by retinoic acid”Oncology53(4):334-340 (1996).
Kim et al., Chem Abstract 116:3391 (1991).
Kini et al., “Synthesis and antitumor activity of ribavirin imidates. A new facile synthesis of ribavirin amidine (1-beta-D-ribofuranosyl-1,24-triazole-3-carboxamidine hydrochloride”J. Med. Chem. 32(7):1447-1449 (1989).
Kini et al. “Synthesis and antiviral activity of certain guanosine analogues in the thiazolo[4,5-d]pyrimidine ring system”J. Med Chem.34:3006-3010 (1991).
Lollini et al., “Systemic effects of cytokines released by gene-transduced tumor cells: marked hyperplasia induced in small bowel by gamma-interferon transfectants through host lymphocytes”Int. J. Cancer61:425-430 (1995).
Marumo et al., “Application of the interferon minipellet to human renal cell carcinoma in nude mice”Int. J. Urol.4:55-61 (1997).
Neuhaus et al., “Multiple sclerosis: Comparison copolymer-1-reactive t cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells”Proc. Natl. Acad. Sci. USA97:7452-7457 (2000).
Ning et al., “Ri

Affiliated with

Also associated with

Rating

Nucleoside analogs with carboxamidine modified monocyclic base does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Nucleoside analogs with carboxamidine modified monocyclic base, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nucleoside analogs with carboxamidine modified monocyclic base will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4088363